Literature DB >> 17364214

Biotechnological challenges of phage therapy.

Mikael Skurnik1, Maria Pajunen, Saija Kiljunen.   

Abstract

The challenges for successful launching of a profitable phage therapeutic product include intellectual property rights, safety issues, reproducibility, stability and robustness of the product. A successful and marketable product would be a highly purified bacteriophage preparation containing one or several fully characterized phages, accompanied by optimized methods of administration and backed up by properly controlled efficacy and safety studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17364214     DOI: 10.1007/s10529-007-9346-1

Source DB:  PubMed          Journal:  Biotechnol Lett        ISSN: 0141-5492            Impact factor:   2.461


  47 in total

1.  Selection and characterization of a multivalent Salmonella phage and its production in a nonpathogenic Escherichia coli strain.

Authors:  S B Santos; E Fernandes; C M Carvalho; S Sillankorva; V N Krylov; E A Pleteneva; O V Shaburova; A Nicolau; E C Ferreira; J Azeredo
Journal:  Appl Environ Microbiol       Date:  2010-09-03       Impact factor: 4.792

2.  Isolation and characterization of Klebsiella pneumoniae specific bacteriophages from sewage samples.

Authors:  S Kumari; K Harjai; S Chhibber
Journal:  Folia Microbiol (Praha)       Date:  2010-06-06       Impact factor: 2.099

3.  Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection.

Authors:  Lisa A Carmody; Jason J Gill; Elizabeth J Summer; Uma S Sajjan; Carlos F Gonzalez; Ryland F Young; John J LiPuma
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

4.  Influence of some environmental variables and addition of r-lysozyme on efficacy of Vibrio harveyi phage for therapy.

Authors:  Tanmoy Gon Choudhury; Biswajit Maiti; M N Venugopal; Indrani Karunasagar
Journal:  J Biosci       Date:  2019-03       Impact factor: 1.826

5.  Combined use of bacteriophage K and a novel bacteriophage to reduce Staphylococcus aureus biofilm formation.

Authors:  D R Alves; A Gaudion; J E Bean; P Perez Esteban; T C Arnot; D R Harper; W Kot; L H Hansen; M C Enright; A Tobias A Jenkins
Journal:  Appl Environ Microbiol       Date:  2014-08-22       Impact factor: 4.792

6.  Phage Therapy: Future Inquiries.

Authors:  Sijia Wu; Elisabeth Zachary; Keenan Wells; Catherine Loc-Carrillo
Journal:  Postdoc J       Date:  2013-06

7.  Characterization of the genome, proteome, and structure of yersiniophage ϕR1-37.

Authors:  Mikael Skurnik; Heidi J Hyytiäinen; Lotta J Happonen; Saija Kiljunen; Neeta Datta; Laura Mattinen; Kirsty Williamson; Paula Kristo; Magdalena Szeliga; Laura Kalin-Mänttäri; Elina Ahola-Iivarinen; Nisse Kalkkinen; Sarah J Butcher
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

8.  Pros and cons of phage therapy.

Authors:  Catherine Loc-Carrillo; Stephen T Abedon
Journal:  Bacteriophage       Date:  2011-03

9.  Phage-encoded colanic acid-degrading enzyme permits lytic phage infection of a capsule-forming resistant mutant Escherichia coli strain.

Authors:  Min Soo Kim; Young Deuk Kim; Sung Sik Hong; Kwangseo Park; Kwan Soo Ko; Heejoon Myung
Journal:  Appl Environ Microbiol       Date:  2014-11-21       Impact factor: 4.792

Review 10.  Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections.

Authors:  Dana Holger; Razieh Kebriaei; Taylor Morrisette; Katherine Lev; Jose Alexander; Michael Rybak
Journal:  Antibiotics (Basel)       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.